Today: 18 May 2026
Saudi Aramco (Saudi Arabian Oil Co) stock falls 2.4% as Saudi shares slide on Iran risk
1 February 2026
1 min read

Saudi Aramco (Saudi Arabian Oil Co) stock falls 2.4% as Saudi shares slide on Iran risk

Riyadh, Feb 1, 2026, 17:33 GMT+3 — The market has closed.

Shares of Saudi Arabian Oil Co (2222) fell 2.4%, ending Sunday at 25.18 riyals. Trading volume hit roughly 9.5 million shares on the Saudi Exchange.

Saudi Arabia’s benchmark index (TASI, the Tadawul All Share Index) dropped 1.9%, marking its steepest intraday decline since April. The slide came amid rising concerns over potential U.S. military action against Iran. Ayatollah Ali Khamenei warned that any American strike would spark a regional conflict. Meanwhile, Washington has bolstered its naval forces following repeated warnings from Donald Trump, the report said.

This is significant for Aramco, as it ranks among the market’s largest components and a crucial dividend provider for local investors. When risk appetite falls in the region, the stock tends to move more on sentiment than on crude oil fundamentals.

Oil is charting its own course. OPEC+ — led by Saudi Arabia and Russia — has tentatively agreed to maintain current output levels through March, according to a draft statement and sources who spoke with Reuters. Eight core members are set to meet later Sunday to finalize the decision. Brent crude ended Friday just shy of $70 a barrel, near the six-month peak of $71.89 touched the day before, despite ongoing debate over whether an oversupply in 2026 might weigh on prices.

On Feb. 1, Aramco’s shares fluctuated from 25.16 to 25.78 riyals, according to Investing.com. The stock’s 52-week range stands at 23.04 to 27.85.

Some investors are closely tracking whether the new foreign-access rules will impact the flow of capital immediately or remain largely theoretical. “This rally comes ahead of foreign participation,” Hamad Al-Olayan, CEO of Villa Capital, told Asharq Al-Awsat. Mohamed Hamdy Omar, CEO of G World, described the change as “a historic step.” Aawsat

The next moves remain unpredictable. Signs of easing tensions between Washington and Tehran might strip oil of its geopolitical premium, weakening support for Aramco. On the other hand, any escalation could keep regional equities under strain, even if crude prices stay steady.

Monday’s session will center on the OPEC+ decision and how oil prices respond, with traders also watching weekend headlines about U.S.-Iran tensions. Early indications on whether foreign investors step up or hold back will be key.

Aramco’s next major event is its full-year 2025 results, scheduled for March 10, per the company’s financial calendar. Investors are closely watching that date for dividend cues and other key updates.

update on spending plans.

Latest articles

Quince Therapeutics Stock Faces Nasdaq Pressure After Fresh QNCX Filing

Quince Therapeutics Stock Faces Nasdaq Pressure After Fresh QNCX Filing

18 May 2026
Quince Therapeutics was last quoted at $1.15 before Monday’s Nasdaq open after Nantahala Capital Management disclosed 7.52% beneficial ownership. The company’s latest filing reported no current product candidates and raised substantial doubt about its ability to continue as a going concern. Quince is seeking shareholder approval for another reverse stock split at its June 11 meeting. The company remains out of compliance with Nasdaq’s $50 million market value rule.
Macy’s Gains Pre-Market as Berkshire Buys In — What’s Ahead for Traders

Macy’s Gains Pre-Market as Berkshire Buys In — What’s Ahead for Traders

18 May 2026
Macy’s shares rose in premarket trading after Berkshire Hathaway disclosed a new stake of 3.04 million shares, valued at about $55 million as of March 31. The stock closed Friday at $18.41 and last traded at $18.99 premarket with 128,170 shares exchanged. Macy’s will report first-quarter results on June 3. Tariffs, fuel costs, and weak discretionary spending remain risks for the retailer.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

18 May 2026
ImmunityBio said Monday five U.S. patents protect its Anktiva-plus-BCG bladder cancer treatment through at least 2035, following an exclusive U.S. supply deal with Japan BCG Laboratory. The company plans to seek FDA approval for the Tokyo-172 BCG strain, which is not yet approved in the U.S. ImmunityBio shares last traded at $7.97 before the Nasdaq open.
Why Virax Biolabs Stock Is Jumping Before the Bell Today

Why Virax Biolabs Stock Is Jumping Before the Bell Today

18 May 2026
Virax Biolabs shares jumped in pre-market trading Monday, indicated at $0.3458 after closing Friday at $0.1535. The move followed a sponsored TV segment featuring CEO James Foster and a new SEC filing showing Armistice Capital holds 4.99% of shares. ViraxImmune, the company’s main test, remains in development and is not approved for diagnostic use. No new company press release appeared over the weekend.

Popular

Bitmine Faces $13.4B Ether Position Into Monday After Weekend Drop

Bitmine Faces $13.4B Ether Position Into Monday After Weekend Drop

17 May 2026
Bitmine Immersion Technologies shares fell 9.7% to $19.87 Friday, capping a 10.4% weekly drop, as Ether slid to $2,186, below the $2,366 price Bitmine used in its latest update. The company holds 5.21 million ETH, now worth about $11.4 billion, nearly $1 billion less than its May 10 valuation. Trading resumes Monday.
Bitcoin price breaks below $80,000 after silver rout — and Warren Buffett’s Berkshire Hathaway sees American Express nearly catch Apple
Previous Story

Bitcoin price breaks below $80,000 after silver rout — and Warren Buffett’s Berkshire Hathaway sees American Express nearly catch Apple

Netflix stock price: co-CEO share sale and Senate hearing put NFLX in play for the week ahead
Next Story

Netflix stock price: co-CEO share sale and Senate hearing put NFLX in play for the week ahead

Go toTop